

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	<b>MAIL STOP AMENDMENT</b>
Nicholas Bodor et al.	)	Group Art Unit: 1623
Application No.: 10/551,205	)	Examiner: JONATHAN S LAU
Filed: November 14, 2006	)	Confirmation No.: 4092
For: ORAL FORMULATIONS OF	)	
CLADRIBINE	)	
	)	
	)	
	)	
	)	

**SIXTH INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Applicants request the Examiner's consideration of the document listed on the accompanying Form PTO-1449.

Pursuant to 37 C.F.R. § 1.98, a copy of the document cited is enclosed.

This Statement, Form PTO-1449 and document are being submitted after the issuance of an Official Action on the merits but prior to the final action, therefore under 37 C.F.R. § 1.97(c), the fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

A fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is enclosed.

It is respectfully requested that an Examiner-initialed copy of Form PTO-1449 be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: December 16, 2009

By: Mary Katherine Baumeister  
Mary Katherine Baumeister  
Registration No. 26254

**Customer No. 21839**  
703 836 6620